Tempest Therapeutics, Inc. - TPST Operating profit EBITDA
The success of Tempest Therapeutics (TPST) depends on clinical trial outcomes and the rate of cash burn. EBITDA_Co dynamics demonstrate the ability to act as a cash generator under market pressure, where 0.00 is the current level of the indicator. Tempest Therapeutics (TPST) develops small molecules to combat tumors, focusing on PPAR inhibitors. Simultaneously, the business is mitigating risks by creating metabolic drugs for the therapy of colorectal and liver cancers.
Tempest Therapeutics, Inc. (TPST) - metric breakdowns and financial figures
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Aggregate Debt to Capital Tempest Therapeutics|TPST - Long-Term Debt to Capital|Current Liabilities to Capital Tempest Therapeutics Inc|TPST - Company Debts|Debt to Book Value Tempest Therapeutics|TPST - Company Long-Term Debt|Current Liabilities Tempest Therapeutics|Immediate Liquidity tempesttx.com
- earnings and market ratios statistics:
TPST - Company Net Income|Company Profit Forecast Tempest Therapeutics|TPST - Price to Earnings Ratio|Market Cap to Future Earnings Ratio tempesttx.com|TPST - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Tempest Therapeutics|TPST - Operating profit before deduction of amortization|Earnings per share for the last four quarters Tempest Therapeutics|TPST - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months tempesttx.com|TPST - Earnings growth in current year|Expected net earnings per share growth next year Tempest Therapeutics
Analysis of all company metrics:TPST - Tempest Therapeutics Corp
This indicator measures cash flow from core operations before taxes and debt obligations, allowing for an assessment of the business's actual ability to generate resources in an environment of expensive capital. By analyzing the total operating profit of Tempest Therapeutics (TPST), an investor can gauge the financial stability of Tempest Therapeutics (TPST) while developing innovative oncology drugs and scaling methods for activating the immune response against liver tumors.
Competitors of Tempest Therapeutics (TPST)
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Operating profit before deduction of amortization PSNL (Personalis, Inc.)|Company profit before taxes, interest and amortization ERAS|Operating profit EBITDA DCTH (Delcath Systems)|Y-mAbs Therapeutics Inc (YMAB) - Profit before interest, taxes and amortization|AURA - Profit before payment of interest, taxes and amortization|Candel Therapeutics (CADL) - Operating profit before deduction of amortization|Accuray Incorporated (ARAY) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization SLS (SELLAS Life Sciences Group)|ACTU (Actuate Therapeutics) - Operating profit EBITDA|Profit before interest, taxes and amortization Citius Oncology Inc. CTOR|Profit before payment of interest, taxes and amortization TuHURA Biosciences, Inc. (HURA)|Operating income before deduction of amortization Protara Tx|Fate Therapeutics, Inc. - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization WHWK (Aadi Bioscience, Inc.)|TCRX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization CSBR (Champions Oncology)|XBIT (xbiotech.com) - Operating profit before deduction of amortization|CVM: Company profit before taxes, interest and amortization|OSTX (OS Therapies Incorporated) - Operating profit EBITDA|RADX: Income before deduction of interest, taxes and amortization|Operating profit EBITDA ARTV|ANL - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Veru Pharma VERU|Income before deduction of interest, taxes and amortization XLO|Enochian BioSciences - Operating profit EBITDA|MURA - Operating profit EBITDA|kairospharma.com (KAPA) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization OKUR (OnKure Therapeutics)|GDTC (CytoMed Therapeutics Ltd) - Operating profit EBITDA|Profit before interest, taxes and amortization Curis Corp CRIS|Operating profit before deduction of amortization APLM (Apollomics, Inc.)|Operating profit EBITDA tharimmune.com (THAR)|Advanced Biomed - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization GNPX (Genprex Inc.)|Calidi Bio - Operating profit EBITDA|Operating income before deduction of amortization sunshinebiopharma.com SBFM|XBIO: Operating profit EBITDA|Operating profit before deduction of amortization salariuspharma.com|Profit before payment of interest, taxes and amortization Purple Biotech Ltd.|AON (AONC) - Operating income before deduction of amortization|Operating profit before deduction of amortization BGNE (BeOne Medicines)|Company profit before taxes, interest and amortization CKPT|Profit before payment of interest, taxes and amortization Elevation Oncology ELEV|ICAD (iCAD Inc.) - Profit before deduction of interest, taxes, depreciation and amortization|IKNA - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Notable Labs Ltd NTBL|VIRX (viracta.com) - Operating profit before deduction of amortization|MOR: Company profit before taxes, interest and amortization|NAYA (NAYA Biosciences) - Operating profit EBITDA|Operating profit before deduction of amortization ascentage.com (AAPGV)
